Deferoxamine for advanced hepatocellular carcinoma

New England Journal of Medicine

Volumn 365, Issue 6, 2011, Pages 576-578

  Yamasaki, Takahiro ^a   Terai, Shuji ^a   Sakaida, Isao ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEFEROXAMINE;

ADULT; AGED; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; INTERSTITIAL PNEUMONIA; JAPAN; KIDNEY FAILURE; LETTER; LIVER CELL CARCINOMA; LUNG METASTASIS; MALE; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT FAILURE;

EID: 80051615717     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1105726     Document Type: Letter

References (5)

1. Sakaida I, Kayano K, Wasaki S, Nagatomi A, Matsumura Y, Okita K. Protection against acetaminophen-induced liver injury in vivo by an iron chelator, deferoxamine. Scand J Gastroenterol 1995;30:61-7.
2. Sakaida I, Hironaka K, Uchida K, Okita K. Iron chelator deferoxamine reduces preneoplastic lesions in liver induced by choline-deficient L-amino acid-defined diet in rats. Dig Dis Sci 1999;44:560-9. (Pubitemid 29137968)
3. Yu Y, Kovacevic Z, Richardson DR. Tuning cell cycle regulation with an iron key. Cell Cycle 2007;6:1982-94. (Pubitemid 47327885)
4. Donfrancesco A, Deb G, Dominici C, Pileggi D, Castello MA, Helson L. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res 1990;50:4929-30. (Pubitemid 20257912)
5. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.